#1 Clinical Trials Search in Europe

Nusinersen

Nusinersen, also known by its brand name Spinraza, is an innovative drug being studied in clinical trials for the treatment of spinal muscular atrophy (SMA). SMA is a genetic disorder that affects muscle strength and movement. This article explores the use of nusinersen in various clinical trials, its potential benefits, and what researchers are learning about its effectiveness and safety in treating different types of SMA.

Table of Contents

What is Nusinersen?

Nusinersen, also known by its brand name Spinraza, is a groundbreaking medication used to treat spinal muscular atrophy (SMA). It’s also referred to by several other names in scientific literature, including ISIS 396443, BIIB058, and IONIS-SMN Rx[5][9]. This drug was developed to address a critical need in treating SMA, a rare genetic disorder that affects muscle strength and movement.

How Nusinersen Works

Nusinersen is classified as an antisense oligonucleotide. This means it’s a synthetic molecule designed to interact with the genetic material in cells. Specifically, nusinersen works by increasing the production of a protein called survival motor neuron (SMN) protein[10]. In patients with SMA, there’s a deficiency of this protein, which leads to the degeneration of motor neurons – the nerve cells responsible for controlling muscle movement.

By increasing SMN protein production, nusinersen helps to slow down or stop the degradation of motor neurons. This can lead to improvements in muscle strength and motor function in patients with SMA[10].

Conditions Treated by Nusinersen

Nusinersen is primarily used to treat spinal muscular atrophy (SMA). SMA is a genetic disorder that affects the motor neurons in the spinal cord, leading to muscle weakness and atrophy (wasting). There are several types of SMA, ranging from the most severe (Type I) to milder forms (Types II, III, and IV)[10].

Clinical trials have investigated the use of nusinersen in various SMA types, including:

  • Infantile-onset SMA (typically Type I)[3]
  • Later-onset SMA (Types II and III)[2]
  • Presymptomatic infants genetically diagnosed with SMA[7]

How Nusinersen is Administered

Nusinersen is administered through an intrathecal injection. This means the medication is injected directly into the fluid surrounding the spinal cord (called cerebrospinal fluid or CSF) through a needle inserted into the lower back[1]. This method of administration allows the drug to reach the motor neurons in the spinal cord more effectively.

The typical dosing schedule for nusinersen includes:

  1. Loading doses: Initially, patients receive four loading doses. These are usually given on days 0, 14, 28, and 63[1].
  2. Maintenance doses: After the loading doses, patients receive maintenance doses every four months[1].

Each dose of nusinersen is typically 12 mg (5 mL) for standard treatment[1]. However, some studies are exploring higher doses, such as 50 mg loading doses followed by 28 mg maintenance doses[8].

Efficacy of Nusinersen

Clinical trials have shown promising results for nusinersen in treating SMA. Some of the key findings include:

  • Improved motor function: Many patients treated with nusinersen showed improvements in motor milestones, as measured by scales like the Hammersmith Infant Neurological Examination (HINE) and the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)[2][3].
  • Increased survival: Studies have shown that nusinersen can increase survival rates and delay the need for permanent ventilation in infants with SMA[7].
  • Benefits for older patients: Even adults with SMA have shown improvements in muscle strength and function after treatment with nusinersen[1].

Safety and Side Effects

Nusinersen has been generally well-tolerated in clinical trials. However, like all medications, it can cause side effects. Some of the potential side effects and safety considerations include:

  • Injection site reactions: Since nusinersen is administered through a spinal injection, there can be side effects related to the procedure, such as headache, back pain, or nausea[2].
  • Respiratory issues: Some patients may experience respiratory infections or other breathing problems[2].
  • Laboratory abnormalities: Changes in blood and urine tests have been observed in some patients[5].

It’s important to note that the benefits of nusinersen in treating SMA often outweigh these potential risks for many patients. However, treatment decisions should always be made in consultation with healthcare providers.

Ongoing Research

Research on nusinersen is ongoing, with several studies exploring its long-term effects, use in different patient populations, and potential combination with other treatments. Some areas of current research include:

  • Higher dose regimens: Studies are investigating whether higher doses of nusinersen might provide additional benefits[8].
  • Use in patients previously treated with other SMA therapies: Researchers are studying how nusinersen works in patients who have previously received other treatments for SMA[6].
  • Effects on involuntary movements: Some studies are looking at how nusinersen might affect tremors and other involuntary movements that can occur in SMA patients[10].

These ongoing studies aim to further improve our understanding of nusinersen and optimize its use in treating SMA, potentially expanding its benefits to more patients in the future.

Aspect Details
Drug Name Nusinersen (Spinraza)
Condition Treated Spinal Muscular Atrophy (SMA)
Administration Method Intrathecal injection
Age Groups Studied Infants, children, and adults
Key Outcome Measures Motor function, survival rates, achievement of motor milestones
Safety Monitoring Adverse events, laboratory tests, vital signs, neurological examinations
Potential Benefits Improved motor function, increased survival, achievement of motor milestones
Common Side Effects Headache, back pain, nausea (related to lumbar puncture procedure)

FAQ

  • What is nusinersen and how does it work? Nusinersen (Spinraza) is a medication designed to treat spinal muscular atrophy. It works by increasing the production of a protein called survival motor neuron (SMN) protein, which is essential for the health and function of motor neurons. By regulating gene expression, nusinersen helps slow down or stop the degradation of motor neurons in SMA patients.
  • How is nusinersen administered? Nusinersen is administered through intrathecal injection, which means it is injected directly into the fluid surrounding the spinal cord. This is typically done through a procedure called a lumbar puncture or spinal tap.
  • What types of SMA are being studied with nusinersen? Clinical trials are investigating nusinersen in various types of SMA, including infantile-onset SMA (Type I), as well as later-onset types such as Type II, III, and IV. Some studies are also looking at its use in presymptomatic infants with genetically diagnosed SMA.
  • What are some of the potential benefits of nusinersen treatment? Studies have shown that nusinersen may improve motor function, increase survival rates, and help patients achieve motor milestones. Some trials have reported improvements in measures such as the HINE (Hammersmith Infant Neurological Examination) and CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scores.
  • Are there any side effects associated with nusinersen? As with any medication, there can be side effects. Common side effects reported in clinical trials include headache, back pain, and nausea related to the lumbar puncture procedure. Researchers are closely monitoring patients for any adverse events or serious side effects throughout the trials.

Ongoing Clinical Trials on Nusinersen

  • Study on How Nusinersen is Processed in Adults and Children with Spinal Muscular Atrophy Using the ThecaFlex DRx System

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany Italy Poland Spain

  • Study on Higher Doses of Nusinersen for Patients with Spinal Muscular Atrophy Who Previously Participated in a Nusinersen Study

    Not recruiting

    1 1 1
    Investigated drugs:
    Germany Italy Spain

  • Evaluating Higher Dose Nusinersen in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam

    Not recruiting

    1 1 1
    Investigated drugs:
    Germany Hungary Italy

  • Study of Nusinersen for Patients with Spinal Muscular Atrophy Previously Treated with Onasemnogene Abeparvovec

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Germany Italy Spain

Glossary

  • Spinal Muscular Atrophy (SMA): A genetic disorder characterized by weakness and wasting in muscles used for movement. It is caused by a loss of specialized nerve cells, called motor neurons, in the spinal cord and the part of the brain that is connected to the spinal cord.
  • Intrathecal Injection: A method of delivering medication directly into the fluid surrounding the spinal cord, typically through a lumbar puncture procedure.
  • Motor Neurons: Nerve cells that control voluntary muscle movement.
  • HINE (Hammersmith Infant Neurological Examination): A standardized assessment tool used to evaluate motor function in infants, particularly those with SMA.
  • CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders): A test designed to evaluate motor skills in infants with significant muscle weakness, including those with SMA.
  • Cerebrospinal Fluid (CSF): The clear, colorless fluid that surrounds the brain and spinal cord, providing protection and nutrients.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, causes a significant incapacity, or is otherwise considered medically important.
  • Efficacy: The ability of a drug or treatment to produce a desired effect.

References

  1. https://clinicaltrials.gov/study/NCT04591678
  2. https://clinicaltrials.gov/study/NCT02594124
  3. https://clinicaltrials.gov/study/NCT01839656
  4. https://clinicaltrials.gov/study/NCT02052791
  5. https://clinicaltrials.gov/study/NCT01703988
  6. https://clinicaltrials.eu/trial/study-of-nusinersen-for-patients-with-spinal-muscular-atrophy-previously-treated-with-onasemnogene-abeparvovec/
  7. https://clinicaltrials.gov/study/NCT02386553
  8. https://clinicaltrials.eu/trial/evaluating-higher-dose-nusinersen-in-patients-with-spinal-muscular-atrophy-previously-treated-with-risdiplam/
  9. https://clinicaltrials.gov/study/NCT01780246
  10. https://clinicaltrials.gov/study/NCT04825119